Jupiter Wellness gives corporate update including launch of clinical trials

Jupiter Wellness issued a Letter to Shareholders today to provide a corporate update since its last report in September. that letter said, in part: "I would like to take this opportunity to review the significant progress made by your company since the last Letter to Shareholders dated September 15. We have launched or restarted two clinical trials for tinnitus and eczema, both conditions with large patient populations. We have entered the potentially lucrative market of Female Sexual Wellness and obtained or added to our intellectual property portfolio with the addition of our hair loss therapy. We finally had our topical treatment for psoriasis and vitiligo approved by the "FDA of India" and just announced the market launch in India. And lastly, we announced record revenues for the Nine Months ending September 30 vs. the corresponding period in 2021.We have compiled a quick summary of recent developments and an overview of our products and their current disposition – whether already on the market and generating revenues, currently in clinical trials, or in development.":